CCL2 and metabolic dysfunction-associated steatohepatitis: In addition, in mice with moderate NASH (6-week group), treatment with CU06-1004 led to a significant decrease in mRNA expression of M1 macrophage markers such as TNF-α, interleukin-1β (IL-1β), and monocyte chemoattractant protein-1 (MCP-1) compared with the CD group (Fig 3A–3C).